Gastroenterology Research and Practice / 2016 / Article / Tab 1

Research Article

Prevalence and Risk Factors of Gastric Adenoma and Gastric Cancer in Colorectal Cancer Patients

Table 1

Comparison of clinicopathologic features in the subjects with or without UGI lesion in colorectal cancer patients.

VariablesPatients without UGI lesion ()Patients with synchronous and metachronous UGI lesion () valuePatients with metachronous UGI lesion () value

Sex0.0780.060
 Male65 (60.7%)27 (77.1%)18 (81.8%)
 Female42 (39.3%)8 (22.9%)4 (18.2%)
Age (yrs)64.76 ± 11.7268.29 ± 7.900.04868.36 ± 8.010.128
Body weight (kg)58.50 ± 9.2660.78 ± 9.090.91861.91 ± 9.950.650
BMI (body mass index, kg/m2)22.60 ± 3.0523.01 ± 2.970.72323.44 ± 3.130.931
Hypertension33 (30.8%)12 (34.3%)0.7048 (36.4%)0.612
Diabetes19 (17.8%)10 (40.0%)0.1686 (27.3%)0.304
Smoking21 (19.6%)12 (34.3%)0.0757 (31.8%)0.206
Alcohol25 (26.4%)20 (57.1%)<0.00112 (54.5%)0.003
Family history (solid tumor)10 (9.35%)6 (17.1%)0.2054 (18.2%)0.225
Tumor size (cm)5.06 ± 2.394.49 ± 3.020.5044.57 ± 3.460.271
CRC location0.8280.844
 Rt.colon62 (57.9%)21 (60.0%)14 (63.6%)
 Transverse colon4 (3.7%)2 (5.7%)1 (4.6%)
 Lt.colon41 (38.3%)12 (34.3%)7 (31.8%)
Cancer staging0.7490.907
 I22 (20.6%)10 (28.6%)6 (27.3%)
 II42 (39.3%)11 (31.4%)8 (36.4%)
 III36 (33.6%)12 (34.3%)7 (31.8%)
 IV7 (6.5%)2 (5.7%)1 (4.5%)
Vascular invasion84 (78.5%)22 (62.9%)0.06515 (68.2%)0.297
Lymphatic invasion86 (80.4%)21 (60.0%)0.01514 (63.6%)0.087
Differentiation0.0770.147
 Well differentiated2 (1.9%)1 (2.86%)0 (0%)
 Moderate differentiated101 (94.4%)29 (82.9%)19 (86.4%)
 Poorly differentiated4 (3.7%)5 (14.3%)3 (13.6%)
CEA level (ng/mL)8.20 ± 18.716.22 ± 12.310.5305.58 ± 11.200.417
Follow-up duration (month)25.57 ± 23.7536.69 ± 27.550.58129.77 ± 22.40.417

Upper GI lesion includes gastric adenoma or cancer.
Length of the long axis of the tumor.
Tumors located in the cecum and ascending colon were categorized as Rt.colon and those located in descending colon and S-colon, rectum, were categorized as Lt.colon.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.